FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
--	------------------------------------	-----------

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cleveland Paul B						2. Issuer Name and Ticker or Trading Symbol SANGAMO BIOSCIENCES INC [SGMO]								heck all appl	ationship of Reportin call applicable) Director Officer (give title		10% O	ner
(Last) (First) (Middle) C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL				07	3. Date of Earliest Transaction (Month/Day/Year) 07/15/2013								below)		Other (below)		
(Street) RICHMOND CA 94804			- 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Lir	ie) X Form Form	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)															
		Tab	le I - N	on-Deriv	ative	Sec	uritie	s Ac	quired	l, Di	sposed o	of, or Be	eneficia	lly Owne	d			
Date		2. Transac Date (Month/Da	Exec ay/Year) if an		a. Deemed recution Date, any onth/Day/Year)				4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			Benefic	ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)	Price	Transa (Instr. 3	tion(s)			(111501.4)		
Common Stock			07/15/	2013)13			M		8,000	A	\$2.04	8	,000		D		
Common Stock 07/15		07/15/	2013)13		S ⁽¹⁾		8,000	D	\$9.589	7(2)	0		D				
		٦	Table II								posed of converti			y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	e S Illy	Ownershi Form: y Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to	\$2.04	07/15/2013			M		8,000		(3)		11/17/2018	Common	8,000	\$0.00	7,278	3	D	

Explanation of Responses:

Buy)

- 1. The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2013.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.4801 to \$9.6901, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- 3. All shares underlying this option are vested and immediately exercisable

/s/ Florence Tam, Attorney-in-**Fact**

07/17/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.